JP3552260B2 - Optical resolution of 1-amino-2-indanols - Google Patents

Optical resolution of 1-amino-2-indanols Download PDF

Info

Publication number
JP3552260B2
JP3552260B2 JP1044194A JP1044194A JP3552260B2 JP 3552260 B2 JP3552260 B2 JP 3552260B2 JP 1044194 A JP1044194 A JP 1044194A JP 1044194 A JP1044194 A JP 1044194A JP 3552260 B2 JP3552260 B2 JP 3552260B2
Authority
JP
Japan
Prior art keywords
formula
amino
iii
indanol
indanols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP1044194A
Other languages
Japanese (ja)
Other versions
JPH07215922A (en
Inventor
浩郎 松本
義夫 小原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Priority to JP1044194A priority Critical patent/JP3552260B2/en
Publication of JPH07215922A publication Critical patent/JPH07215922A/en
Application granted granted Critical
Publication of JP3552260B2 publication Critical patent/JP3552260B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【0001】
【産業上の利用分野】
本発明は医農薬の合成中間体として有用な光学活性1−アミノ−2−インダノール類の光学分割法及び分割の過程で生成するジアステレオマー塩に関する。
【0002】
【従来の技術及び発明が解決しようとする課題】
式[(±)−I]又は式[(±)−II]で表される1−アミノ−2−インダノール類(式中、R、R、R及びRは、それぞれ独立して、水素原子、C−Cアルキル基、C−Cアルコキシ基、ハロゲン原子、シアノ基又はニトロ基を意味する。)は、それぞれ2個の不斉炭素を有しており、それぞれ2種の光学異性体が存在する([(+)−I]、[(−)−I]、[(+)−II]及び[(−)−II]と表記する。)。
【0003】
【化2】

Figure 0003552260
【0004】
それらは光学異性体間で薬理活性や安全性の異なることの多い医農薬、とりわけ医薬の合成中間体として有用であり、例えばJ. Med. Chem. 1992年, 35巻, 1685 − 1701 頁の文献には光学活性シス−1−アミノ−2−インダノールの重要性が示されている。
同文献によれば、シス体はトランス体の反転法(反応式1を参照)により合成されるため、光学活性トランス−1−アミノ−2−インダノールも又重要な合成中間体である。
【0005】
【化3】
Figure 0003552260
【0006】
[式中、BOC‐Phe−OHは、N−t−ブトキシカルボニル−L−(又は−D−)フェニルアラニンを、HO−BTは、1−ヒドロキシベンゾトリアゾールを、TFAはトリフルオロ酢酸を表す。]
【0007】
上記の文献に記載されているシス−1−アミノ−2−インダノールの光学分割法を反応式1に示した。光学活性フェニルアラニン誘導体とのジアステレオマーを利用する方法であるが、クロマト分離するなど、工業的かつ経済的な方法とはいい難い。具体的に説明すれば、既知の方法により2−ブロモ−1−インダノールから容易に得られるトランス−1−アミノ−2−インダノールをベンゾイル化した後、チオニルクロリドを作用させて得られるオキサゾール環化合物を硫酸により加水分解し、アミノ基を保護したL−フェニルアラニンとの縮合の後に脱保護すれば、シリカゲルの低圧カラムクロマトグラフィーにより分離し得るジアステレオマー混合物となることを特徴とする方法である。この化合物は分離後、L−フェニルアラニン部分をはずすことによって目的とする(−)−シス−1−アミノ−2−インダノールに変換できる。
【0008】
【課題を解決するための手段】
本発明者らは工業化可能な製造技術の確立を目指し、式[(±)−I]又は式[(±)−II]で表される1−アミノ−2−インダノール類(式中、R、R、R及びRは、上記に同じ。)の光学分割剤を探索したところ、農薬(除草剤)の製造原料として大量かつ安価に入手可能な光学活性カルボン酸(式[(+)−III]又は式[(−)−III])を見いだし、本発明を完成するに至った。
【0009】
【化4】
Figure 0003552260
【0010】
即ち、本発明はラセミ体である式[(±)−I] 又は式[(±)−II]で表される1−アミノ−2−インダノール類(式中、R、R、R及びRは、上記に同じ。)を式[(+)−III]又は式[(−)−III]で表される光学活性カルボン酸と反応させた後、生成するジアステレオマー塩を分離することを特徴とする式[(±)−I] 又は式[(±)−II]で表される1−アミノ−2−インダノール類の光学分割法及び分割の過程で生成するジアステレオマー塩に関する。
【0011】
以下、化合物[(±)−I]を光学分割し、化合物[(+)−I]及びその対掌体[(−)−I]を得る方法について説明する(反応式2参照)。この方法は化合物[(±)−II]を光学分割する際にも同様に適用することができる。
化合物[(±)−I]は、上記の文献J. Med. Chem. 1992年, 35巻, 1685 − 1701 頁に記載された方法に従い、容易に合成することができる。又、光学分割剤である化合物[(+)−III]又は式[(−)−III]は、特開昭61−83144号に記載した方法に従い合成することができる。
【0012】
【化5】
Figure 0003552260
【0013】
工程Aにおいて、適当な溶媒中、化合物[(±)−I]に対して、光学分割剤である化合物[(+)−III]を反応させ、晶析を行なうとジアステレオマー塩[(−)−I・(+)−III]を容易に結晶として得ることができる。この時、使用する溶媒(例えば、アセトン)によっては、それ自身が、結晶溶媒としてジアステレオマー塩に取り込まれることがあるが、光学分割に支障はない。化合物[(+)−I]及び[(−)−I]の旋光度の符号[(+)、(−)]はエタノール中での測定結果をもとにしている。同様に、光学分割剤として化合物[(−)−III]を用いるとジアステレオマー塩[(+)−I・(−)−III] を得ることができる。従って、光学分割剤を選択することにより、化合物[(±)−I] の所望の光学異性体を容易に得ることができる。
【0014】
工程Aで使用する溶媒としては特に制限はないが、アセトン、メチルイソブチルケトンなどのケトン系の溶媒が好ましい。
反応温度は−20〜100℃の範囲、好ましくは10〜30℃の範囲がよい。
晶析温度は−20〜50℃の範囲、好ましくは−10〜20℃の範囲がよい。
必要であれば晶析したジアステレオマー塩を再結晶して、さらに光学純度の高い結晶性のジアステレオマー塩を得ることもできる。
【0015】
工程Bにおいては、工程Aで得られた結晶性のジアステレオマー塩[(−)−I・(+)−III]に、炭酸水素ナトリウム、炭酸水素カリウム、炭酸ナトリウム、炭酸カリウム、水酸化ナトリウム及び水酸化カリウム等から選ばれるアルカリ水溶液を作用させてエタノール中での旋光度が左旋性を示す目的の光学活性アミン[(−)−I]を晶析させるか、又は有機溶媒で抽出することができる。あるいは酸処理の後、光学活性カルボン酸を有機溶媒抽出により除去した後に、水層をアルカリ性にすることにより目的の光学活性アミン[(−)−I]を晶析させるか、有機溶媒で抽出することもできる。。
【0016】
化合物[(−)−I]の光学純度はメチルイソシアネートと反応させて式[IV]のウレア化合物に誘導した後、光学異性体分離用の液体クロマトグラフィーカラム(ダイセル社、キラルセルOC等)を用いて分析することにより測定することができる。同様にして化合物[(+)−I]の光学純度も測定することができる。
【0017】
【化6】
Figure 0003552260
【0018】
本発明の光学分割法を適用できる式[(±)−I] 又は式[(±)−II]で表される1−アミノ−2−インダノール類の置換基であるR、R、R及びRは、それぞれ独立して、水素原子、C−Cアルキル基、C−Cアルコキシ基、ハロゲン原子、シアノ基、又はニトロ基を意味する。
−Cアルキル基として、メチル、エチル、プロピル、i−プロピル、ブチル、i−ブチル、sec−ブチル及びt−ブチルが挙げられる。
【0019】
−Cアルコキシ基として、メトキシ、エトキシ、プロポキシ、i−プロポキシ、ブトキシ、i−ブトキシ、sec−ブトキシ及びt−ブトキシが挙げられる。
ハロゲン原子としては、フッ素原子、塩素原子、臭素原子及びヨウ素原子が挙げられる。
【0020】
[(±)−I] 又は式[(±)−II]で表される1−アミノ−2−インダノール類として、好ましくは、R、R、R及びRが水素原子であるトランス−1−アミノ−2−インダノール又はシス−1−アミノ−2−インダノールを挙げることができる。
【0021】
【実施例】
以下、実施例により本発明をさらに詳細に説明する。
【0022】
実施例1
【0023】
[工程A]
(±)−トランス−1−アミノ−2−インダノール(化合物[(±)−I] ) 2.98 g( 20.0 mmol ) 及び (−)−2−(4−ヒドロキシフェノキシ)プロピオン酸(化合物[(−)−III])3.70 g ( 20.3 mmol )をアセトン 14.9 g に懸濁し、撹拌しながら加熱、還流させた。還流中にジアステレオマー塩の結晶が析出したのを確認した後、水冷して室温( 18℃)付近まで冷却し、撹拌下に30分間晶析させた。さらに撹拌を止めて冷蔵庫中( 5℃)に5時間放置した。析出した結晶を吸引濾過し、冷アセトン 7.0 gで洗浄後、減圧下室温で乾燥すると、無色結晶のジアステレオマー塩アセトン溶媒和物([(+)−I・(−)−III・アセトン] )3.25 g ( y 42% )が得られた。
IRスペクトル(cm−1): 3273, 1682, 1581, 1508, 1456, 1406, 1288, 1261, 1223, 1134, 1093, 1043, 829, 756
【0024】
[工程B]
工程Aで得られたジアステレオマー塩アセトン溶媒和物([(+)−I・(−)−III・アセトン] )3.00 g ( 7.70 mmol )にクロロホルム 100 ml 、水 100 ml 、炭酸ナトリウム 1.00 g( 9.43 mmol )、塩化ナトリウム 20.0 g を加えて振とうし、静置後、分液した。水層は、さらにクロロホルム 70 mlずつ2回で抽出し、クロロホルム層は合わせて無水硫酸ナトリウム( 30 g )と無水炭酸カリウム( 1.5 g )を加えて乾燥した。固形物は濾過し、溶媒留去することによって、無色の (+)−トランス−1−アミノ−2−インダノール 1.09 g ( y 95 % )を得た。
【0025】
この (−)−トランス−1−アミノ−2−インダノール 15 mgを取り、塩化メチレン 0.2 ml 中に懸濁し、メチルイソシアネートを一滴(約 20 mg)加えて2分間振とうした。さらに5分間放置した後、メタノール 5 ml を加えて加熱、溶解し、光学純度分析用のサンプルとした。
(光学純度分析)
光学異性体分離用カラム:キラルセルOC(ダイセル社)
溶離液:ヘキサン−イソプロパノール(4/1)
カラム温度:40℃
流量:0.7 ml/ min
検出方法:UV ( 254 nm )
保持時間:(+)体 14.9 min、(−)体 17.5 min
分析結果:97 %e.e.[0001]
[Industrial applications]
The present invention relates to an optically resolving method for optically active 1-amino-2-indanols useful as a synthetic intermediate for medicinal and agricultural chemicals and to a diastereomer salt formed during the resolving process.
[0002]
Problems to be solved by the prior art and the invention
1-amino-2-indanols represented by the formula [(±) -I] or [(±) -II] (wherein R 1 , R 2 , R 3 and R 4 are each independently , A hydrogen atom, a C 1 -C 4 alkyl group, a C 1 -C 4 alkoxy group, a halogen atom, a cyano group or a nitro group) have two asymmetric carbons, There are species of optical isomers (denoted as [(+)-I], [(-)-I], [(+)-II] and [(-)-II]).
[0003]
Embedded image
Figure 0003552260
[0004]
They are useful as synthetic intermediates of pharmaceuticals and agrochemicals, especially pharmaceuticals, whose pharmacological activity and safety often differ between optical isomers. Med. Chem. The literature of 1992, 35, 1685-1701 indicates the importance of optically active cis-1-amino-2-indanol.
According to the document, the cis-form is synthesized by a trans-form inversion method (see Reaction Scheme 1), and thus optically active trans-1-amino-2-indanol is also an important synthetic intermediate.
[0005]
Embedded image
Figure 0003552260
[0006]
[Wherein, BOC-Phe-OH represents Nt-butoxycarbonyl-L- (or -D-) phenylalanine, HO-BT represents 1-hydroxybenzotriazole, and TFA represents trifluoroacetic acid. ]
[0007]
The optical resolution method of cis-1-amino-2-indanol described in the above literature is shown in Reaction Formula 1. This is a method utilizing a diastereomer with an optically active phenylalanine derivative, but it is difficult to say that it is an industrial and economical method such as chromatographic separation. More specifically, an oxazole ring compound obtained by benzoylating trans-1-amino-2-indanol easily obtained from 2-bromo-1-indanol by a known method and then reacting with thionyl chloride is used. Hydrolysis with sulfuric acid, followed by condensation with amino-protected L-phenylalanine, followed by deprotection, results in a diastereomer mixture that can be separated by low pressure column chromatography on silica gel. After separation, this compound can be converted to the desired (-)-cis-1-amino-2-indanol by removing the L-phenylalanine moiety.
[0008]
[Means for Solving the Problems]
The present inventors aimed at establishing a production technology that can be industrialized, and aimed at establishing 1-amino-2-indanols represented by the formula [(±) -I] or [(±) -II] (wherein R 1 , R 2 , R 3 and R 4 are the same as described above, and the optically active carboxylic acid (formula [(+ ) -III] or the formula [(-)-III]), thereby completing the present invention.
[0009]
Embedded image
Figure 0003552260
[0010]
That is, the present invention relates to 1-amino-2-indanols represented by the formula [(±) -I] or the formula [(±) -II], wherein R 1 , R 2 , and R 3 are racemic. And R 4 are the same as described above.) With an optically active carboxylic acid represented by the formula [(+)-III] or [(−)-III], and then separating the resulting diastereomer salt. Diastereomeric salts of 1-amino-2-indanols represented by the formula [(±) -I] or the formula [(±) -II], which are formed during the resolution process About.
[0011]
Hereinafter, a method of optically resolving the compound [(±) -I] to obtain the compound [(+)-I] and its enantiomer [(-)-I] will be described (see Reaction Scheme 2). This method can be similarly applied to the optical resolution of the compound [(±) -II].
Compound [(±) -I] is described in J. Appl. Med. Chem. The compound can be easily synthesized according to the method described in 1992, 35, 1685-1701. The compound [(+)-III] or the formula [(-)-III] as an optical resolving agent can be synthesized according to the method described in JP-A-61-83144.
[0012]
Embedded image
Figure 0003552260
[0013]
In step A, compound [(±) -I] is reacted with compound [(+)-III] as an optical resolving agent in a suitable solvent, and crystallization is performed to obtain a diastereomer salt [(− ) -I. (+)-III] can be easily obtained as crystals. At this time, depending on the solvent used (for example, acetone), the solvent itself may be taken into the diastereomer salt as a crystallization solvent, but this does not hinder the optical resolution. The signs [(+), (-)] of the optical rotations of the compounds [(+)-I] and [(-)-I] are based on the measurement results in ethanol. Similarly, when the compound [(-)-III] is used as an optical resolving agent, a diastereomer salt [(+)-I. (-)-III] can be obtained. Therefore, a desired optical isomer of the compound [(±) -I] can be easily obtained by selecting an optical resolving agent.
[0014]
The solvent used in step A is not particularly limited, but is preferably a ketone-based solvent such as acetone and methyl isobutyl ketone.
The reaction temperature is in the range of -20 to 100C, preferably in the range of 10 to 30C.
The crystallization temperature is in the range of -20 to 50C, preferably in the range of -10 to 20C.
If necessary, the crystallized diastereomer salt can be recrystallized to obtain a crystalline diastereomer salt having higher optical purity.
[0015]
In step B, the crystalline diastereomer salt [(−)-I. (+)-III] obtained in step A is added to sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide And an aqueous alkali solution selected from potassium hydroxide and the like is allowed to act to crystallize the objective optically active amine [(−)-I] having a left-handed rotation in ethanol, or to extract with an organic solvent. Can be. Alternatively, after the acid treatment, the optically active carboxylic acid is removed by extraction with an organic solvent, and then the aqueous layer is made alkaline to crystallize the desired optically active amine [(−)-I], or extracted with an organic solvent. You can also. .
[0016]
The optical purity of the compound [(−)-I] is determined by reacting with methyl isocyanate to derive the urea compound of the formula [IV], and then using a liquid chromatography column for separating optical isomers (Daicel, Chiralcel OC, etc.). It can be measured by performing analysis. Similarly, the optical purity of the compound [(+)-I] can be measured.
[0017]
Embedded image
Figure 0003552260
[0018]
R 1 , R 2 , R which are substituents of 1-amino-2-indanol represented by the formula [(±) -I] or the formula [(±) -II] to which the optical resolution method of the present invention can be applied. 3 and R 4 each independently represent a hydrogen atom, a C 1 -C 4 alkyl group, a C 1 -C 4 alkoxy group, a halogen atom, a cyano group, or a nitro group.
As C 1 -C 4 alkyl groups include methyl, ethyl, propyl, i- propyl, butyl, i- butyl, sec- butyl and t- butyl.
[0019]
C 1 -C 4 alkoxy groups include methoxy, ethoxy, propoxy, i-propoxy, butoxy, i-butoxy, sec-butoxy and t-butoxy.
Examples of the halogen atom include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
[0020]
As the 1-amino-2-indanol represented by [(±) -I] or the formula [(±) -II], preferably, a trans wherein R 1 , R 2 , R 3 and R 4 are hydrogen atoms. Examples thereof include -1-amino-2-indanol or cis-1-amino-2-indanol.
[0021]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples.
[0022]
Example 1
[0023]
[Step A]
2.98 g (20.0 mmol) of (±) -trans-1-amino-2-indanol (compound [(±) -I]) and (−)-2- (4-hydroxyphenoxy) propionic acid (compound [(-)-III]) 3.70 g (20.3 mmol) was suspended in 14.9 g of acetone, and heated and refluxed with stirring. After confirming that diastereomer salt crystals were precipitated during the reflux, the mixture was cooled with water and cooled to around room temperature (18 ° C.), and crystallized with stirring for 30 minutes. The stirring was stopped, and the mixture was left in a refrigerator (5 ° C.) for 5 hours. The precipitated crystals were filtered by suction, washed with 7.0 g of cold acetone, and dried at room temperature under reduced pressure to give a diastereomer salt acetone solvate of colorless crystals ([(+)-I. (-)-III. Acetone]) 3.25 g (y 42%) was obtained.
IR spectrum (cm -1 ): 3273, 1682, 1581, 1508, 1456, 1406, 1288, 1261, 1223, 1134, 1093, 1043, 829, 756
[0024]
[Step B]
100 ml of chloroform, 100 ml of water, and 3.00 g (7.70 mmol) of the diastereomer salt acetone solvate ([(+)-I. (-)-III.acetone]) obtained in the step A were added. 1.00 g (9.43 mmol) of sodium carbonate and 20.0 g of sodium chloride were added, shaken, allowed to stand, and separated. The aqueous layer was further extracted twice with 70 ml of chloroform each, and the combined chloroform layers were dried by adding anhydrous sodium sulfate (30 g) and anhydrous potassium carbonate (1.5 g). The solid was filtered and the solvent was distilled off to obtain 1.09 g (y95%) of colorless (+)-trans-1-amino-2-indanol.
[0025]
15 mg of this (-)-trans-1-amino-2-indanol was taken, suspended in 0.2 ml of methylene chloride, and one drop (about 20 mg) of methyl isocyanate was added thereto, followed by shaking for 2 minutes. After further standing for 5 minutes, 5 ml of methanol was added, heated and dissolved to obtain a sample for optical purity analysis.
(Optical purity analysis)
Optical isomer separation column: Chiral Cell OC (Daicel)
Eluent: hexane-isopropanol (4/1)
Column temperature: 40 ° C
Flow rate: 0.7 ml / min
Detection method: UV (254 nm)
Retention time: (+) form 14.9 min, (-) form 17.5 min
Analysis result: 97% e. e.

Claims (4)

式[(±)−I]又は式[(±)−II]で表される1−アミノ−2−インダノール類(式中、R、R、R及びRは、それぞれ独立して、水素原子、C−Cアルキル基、C−Cアルコキシ基、ハロゲン原子、シアノ基又はニトロ基を意味する。)を式[(+)−III]又は式[(−)−III]で表される光学活性カルボン酸と反応させた後、生成するジアステレオマー塩を分離することを特徴とする式[(±)−I] 又は式[(±)−II]で表される1−アミノ−2−インダノール類の光学分割法。
Figure 0003552260
1-amino-2-indanols represented by the formula [(±) -I] or [(±) -II] (wherein R 1 , R 2 , R 3 and R 4 are each independently , A hydrogen atom, a C 1 -C 4 alkyl group, a C 1 -C 4 alkoxy group, a halogen atom, a cyano group or a nitro group) with the formula [(+)-III] or the formula [(−)-III After reacting with an optically active carboxylic acid represented by the formula [(±) -I] or [(±) -II], wherein the resulting diastereomer salt is separated. Optical resolution method of 1-amino-2-indanols.
Figure 0003552260
請求項1記載の式[(±)−I] 又は式[(±)−II]で表される1−アミノ−2−インダノール類を式[(+)−III]又は式[(−)−III]で表される光学活性カルボン酸と反応させた後に生成するジアステレオマー塩。The 1-amino-2-indanols represented by the formula [(±) -I] or the formula [(±) -II] according to claim 1 are converted into the formula [(+)-III] or the formula [(−)- A diastereomer salt formed after the reaction with the optically active carboxylic acid represented by III). 式[(±)−I]のR、R、R及びRが水素原子であるトランス−1−アミノ−2−インダノール又はシス−1−アミノ−2−インダノールを光学分割する請求項1記載の方法。Formula [(±) -I] R 1 , R 2, R 3 and claim wherein R 4 to splitting optical trans-1-amino-2-indanol, or cis -1-amino-2-indanol is a hydrogen atom The method of claim 1. 式[(±)−I]のR、R、R及びRが水素原子であるトランス−1−アミノ−2−インダノール又はシス−1−アミノ−2−インダノールを式[(+)−III]又は式[(−)−III]で表される光学活性カルボン酸と反応させた後に生成する請求項2記載のジアステレオマー塩。Trans-1-amino-2-indanol or cis-1-amino-2-indanol in which R 1 , R 2 , R 3 and R 4 in the formula [(±) -I] are hydrogen atoms is converted to a compound of the formula [(+) The diastereomer salt according to claim 2, which is formed after reacting with an optically active carboxylic acid represented by the formula [-III] or the formula [(-)-III].
JP1044194A 1994-02-01 1994-02-01 Optical resolution of 1-amino-2-indanols Expired - Fee Related JP3552260B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1044194A JP3552260B2 (en) 1994-02-01 1994-02-01 Optical resolution of 1-amino-2-indanols

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1044194A JP3552260B2 (en) 1994-02-01 1994-02-01 Optical resolution of 1-amino-2-indanols

Publications (2)

Publication Number Publication Date
JPH07215922A JPH07215922A (en) 1995-08-15
JP3552260B2 true JP3552260B2 (en) 2004-08-11

Family

ID=11750249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1044194A Expired - Fee Related JP3552260B2 (en) 1994-02-01 1994-02-01 Optical resolution of 1-amino-2-indanols

Country Status (1)

Country Link
JP (1) JP3552260B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146029A1 (en) 2000-04-13 2001-10-17 Nissan Chemical Industries Ltd. Method for optical resolution of piperidine carboxylic acid derivative

Also Published As

Publication number Publication date
JPH07215922A (en) 1995-08-15

Similar Documents

Publication Publication Date Title
JP2011503122A (en) Separation of 4,5-dimethoxy-1- (methylaminomethyl) -benzocyclobutane
IL175488A (en) Process for resolving optionally substituted mandelic acids by salt formation with a chiral base cyclic amide
EP3653607B1 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
JP3552260B2 (en) Optical resolution of 1-amino-2-indanols
HU196052B (en) Process for optical resolving raceme mixtures of alpha-naphtyl-propionic acids
JP3209041B2 (en) Optical resolving agent and process for producing optically active tetrahydrofurancarboxylic acids using the same
JP4728636B2 (en) Process for producing optically active amino acids
JP4138928B2 (en) Method for producing D-alloisoleucine and intermediate for production
JPH07330732A (en) Optically active 3-amino-1-benzylpiperidine derivative
JPH02306942A (en) Production of optically active phenylethylamine derivative
JP4126921B2 (en) Process for producing optically active β-phenylalanine derivative
JP4093608B2 (en) Process for producing optically active 2-phenoxypropionic acid
JP4728548B2 (en) Method for producing optically active amino alcohol
JP3157118B2 (en) Optical resolution method of piperidine derivative using acylamino acid
WO1998029398A1 (en) Process for preparing optically active 2-piperazinecarboxylic acid derivatives
JPH05271169A (en) New optically active t-leucine-1-@(3754/24)4-substituted phenyl) ethanesulfonic acid salt and its production
JPH11322665A (en) Purification of optically active alpha-trifluoromethyl lactic acid
JP4868301B2 (en) Process for producing optically active 2- (4-biphenyl) propionic acid
JP2002332277A (en) Method for manufacturing optically active 2- methylpiperazine
JP2000178253A (en) Production of optically active pipecolic acid
JPS61501704A (en) Method for producing optically active phenylalanine and their N-acyl derivatives and novel diastereomeric salts of these compounds
JPH0827073A (en) Racemization of optically active alpha-aryl alkylamine
JP3875315B2 (en) Process for producing optically active acylsulfonamides
JP2859657B2 (en) Optical resolution of (±) -2- (3-benzoyl) phenylpropionic acid
CA3154610A1 (en) An industrial process for resolution of chlocyphos

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20040310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040426

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090514

Year of fee payment: 5

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090514

Year of fee payment: 5

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100514

Year of fee payment: 6

LAPS Cancellation because of no payment of annual fees